Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cinqair

- PMLiVE

FDA approves first biosimilar

Novartis’ Sandoz unit gains new licence for Neupogen copycat

FDA launches drug shortages mobile app

USregulator offers the public and HCPs Android and iPhone versions of the app

Eli Lilly HQ

Lilly delays filing of Lantus rival on safety concerns

Concerns over changes in liver fat detected in phase III trials

Eli Lilly HQ

Lilly sets back evacetrapib data deadline

Cholesterol drug trials extended by six months

- PMLiVE

Apotex latest to file Neupogen biosimilar in the US

White blood cell stimulator could be on the market this year

- PMLiVE

FDA outlines its plans to simplify DTC ads for consumers

Hopes customer-friendly terminology will aid healthcare decisions

Sanofi reception

Generic competition for Sanofi’s Renvela hits UK market

Teva and others launch cheaper versions of the chronic kidney disease drug

Sanofi reception

Generic competition for Sanofi’s Renvela hits UK market

Teva and others launch cheaper versions of the chronic kidney disease drug

- PMLiVE

Hamburg to resign as FDA commissioner

She has held the role for nearly six years

- PMLiVE

Merck’s hep C drug no longer a ‘breakthrough’

FDA rescinds designation for grazoprevir/elbasvir due to approval of other treatments

- PMLiVE

FDA approves first continuous glucose monitoring app

Clears remote blood sugar monitor Dexcom Share

- PMLiVE

Pfizer’s Ibrance wins early breast cancer approval in US

FDA’s decision come two months ahead of schedule

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links